Tempus Receives US FDA Approval for xT CDx, a NGS-Based In Vitro Diagnostic Device
xT CDx is the company’s first Premarket Approval from the FDA
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
02 May 23
xT CDx is the company’s first Premarket Approval from the FDA
01 May 23
EarlyTect BCD test is a non-invasive, urine-based diagnosis intended to become a new diagnostic option for patients suspected…
28 Apr 23
The acquisition will combine Haystack's highly sensitive minimal-residual disease cancer-detection technology with Quest's oncology, genomics and pathology expertise,…
28 Apr 23
According to GE HealthCare, the MRI agent makes it easier to see aberrant structures or lesions and aids…
27 Apr 23
The expansion of the bkActiv system into urology, colorectal and pelvic floor surgeries is said to provide surgeons…
27 Apr 23
The EchoGo Amyloidosis platform leverages AI to assess echocardiograms and detect cardiac amyloidosis, caused by abnormal protein deposits…
27 Apr 23
Ultra Select's team brings a long history of providing a deep solution set of products and services to…
25 Apr 23
The collaboration and distribution agreement allows Thermo Fisher Scientific to obtain exclusive rights to commercialise Devyser’s post-transplant monitoring…
25 Apr 23
Designed to change the existing standard of care, the Sensible Platform has a 10-minute time-to-result, comparative test pricing,…
25 Apr 23
Virtually painless approach, leveraging HALO technology, improves patient access, affordability, and accuracy in decentralized clinical trials with greater…